CN Patent

CN115785103A — 一种治疗胆管癌药物福巴替尼的合成方法

Assigned to Beijing Kang Lisheng Pharmaceutical Technology Development Co ltd · Expires 2023-03-14 · 3y expired

What this patent protects

本发明公开了一种福巴替尼的合成方法，采用单一构型(S)‑3‑(4‑氨基‑3‑碘‑1H‑吡唑并[3,4‑d]嘧啶‑1‑基)四氢吡咯为起始原料，先进行丙烯酰基对接，再与起始原料1‑乙炔基‑3,5‑二甲氧基苯进行偶联反应，经2步反应得到高纯度福巴替尼。

USPTO Abstract

本发明公开了一种福巴替尼的合成方法，采用单一构型(S)‑3‑(4‑氨基‑3‑碘‑1H‑吡唑并[3,4‑d]嘧啶‑1‑基)四氢吡咯为起始原料，先进行丙烯酰基对接，再与起始原料1‑乙炔基‑3,5‑二甲氧基苯进行偶联反应，经2步反应得到高纯度福巴替尼。

Drugs covered by this patent

Patent Metadata

Patent number
CN115785103A
Jurisdiction
CN
Classification
—
Expires
2023-03-14
Drug substance claim
No
Drug product claim
No
Assignee
Beijing Kang Lisheng Pharmaceutical Technology Development Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.